Data study of HPV immunisation programme
The UK introduced a human papillomavirus (HPV) immunisation programme for girls in 2008 as a bivalent vaccine protecting for HPV-16/18. HPV-16 and HPV-18 are responsible for over 70% of cervical cancers. In 2012 the programme switched to quadrivalent vaccine (HPV-6/11/16/18) which also protects against genital warts.
This population study evaluated the effectiveness through comparison of data in the National Survey of Sexual Attitudes and Lifestyles (Natsal-3) in 2010-12, with Natsal-2 undertaken in 1999-2001.
Urine samples from 2569 sexually-experienced women age 16-44 (Natsal-3) were tested for HPV and compared with results with 1798 women in Natsal-2. In Natsal-3, 4.2% of women age 16-44 years were positive for HPV-16/18 and 2.9% for HPV-6/11 rising to 4.5% and 10.8% respectively in 16-20 year olds. In addition, 20.7% of 16-20 year olds had at least one HPV type included in a new 9-valent vaccine currently being trialled.
...Want to read more?
Unlock full access to RCNi Plus today
Save over 50% on your first three months:
- Customisable clinical dashboard featuring 200+ topics
- Unlimited online access to all 10 RCNi Journals including Primary Health Care
- RCNi Learning featuring 180+ RCN accredited learning modules
- NMC-compliant RCNi Portfolio to build evidence for revalidation
- Personalised newsletters tailored to your interests
This article is not available as part of an institutional subscription. Why is this?
